Skip Navigation

Lupus Research Alliance

Biogen

Lupus Therapeutics Statement on Positive Data from Phase 3 PHOENYCS GO Trial in Moderate-To-Severe Systemic Lupus

November 19, 2024

News from ACR Convergence 2024

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance (LRA), is encouraged by the positive Phase 3...

Investigational Treatment Dapirolizumab Pegol Shows Positive Results in Phase 3 Clinical Trial

September 24, 2024

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, is proud to share positive topline results from...

New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus

August, 2022 We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England...

LRA Brings Encouraging News from European Rheumatology Meeting

June 2, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS)...

Promise of Additional Lupus Therapies Highlighted at ACR 2021 Annual Meeting

November 9, 2021 Results of clinical trials testing many existing and potential lupus treatments were highlighted at the American College...

Promising News from Major Medical Meeting, EULAR

Lupus Research News

Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around...

LRA Celebrates Major Research Breakthroughs in 2019

January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science...

Positive Study Results in Potential Treatment for Cutaneous and Systemic Lupus

Lupus Research News

December 3, 2019 The Lupus Research Alliance (LRA) is pleased to share positive results reported by Biogen Inc. from the...

Positive Early Results for BIIB059 as New Treatment Strategy

February 28, 2019 Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of...